E. Smith, C. Díaz-torné, F. Perez-ruiz, and L. M. March, Epidemiology of gout: an update, Best Pract Res Clin Rheumatol, vol.24, issue.6, pp.811-838, 2010.

R. Morlock, P. Chevalier, and L. Horne, Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective Analysis, Rheumatol Ther, vol.3, issue.1, pp.53-75, 2016.

T. Bardin, S. Bouée, and P. Clerson, Prevalence of Gout in the Adult Population of France, Arthritis Care Res. févr, vol.68, issue.2, pp.261-267, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01187430

A. Shiozawa, S. M. Szabo, A. Bolzani, A. Cheung, and H. K. Choi, Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review, J Rheumatol, vol.44, issue.3, pp.388-96, 2017.

P. T. Williams, Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men, Am J Clin Nutr, vol.87, issue.5, pp.1480-1487, 2008.

G. Desideri, J. G. Puig, and P. Richette, The management of hyperuricemia with urate deposition, Curr Med Res Opin, vol.31, issue.2, pp.27-32, 2015.

M. D. Wechalekar, O. Vinik, and J. Moi, The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors, J Rheumatol Suppl, vol.92, pp.15-25, 2014.

M. A. Becker, P. A. Macdonald, B. J. Hunt, C. Lademacher, and N. Joseph-ridge, Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy, Nucleosides Nucleotides Nucleic Acids, vol.27, issue.6, pp.585-91, 2008.

N. Dalbeth, T. Bardin, M. Doherty, F. Lioté, P. Richette et al., Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN), Nat Rev Rheumatol, vol.13, issue.9, pp.561-569, 2017.

W. Zhang, M. Doherty, and T. Bardin, EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT), Ann Rheum Dis, vol.65, issue.10, pp.1312-1336, 2006.

P. Richette, M. Doherty, and E. Pascual, updated EULAR evidence-based recommendations for the management of gout, Ann Rheum Dis, 2016.

P. H. Dessein, E. A. Shipton, A. E. Stanwix, B. I. Joffe, and J. Ramokgadi, Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study, Ann Rheum Dis, vol.59, issue.7, pp.539-582, 2000.

R. N. Beyl, L. Hughes, and S. Morgan, Update on Importance of Diet in Gout, Am J Med, vol.129, issue.11, pp.1153-1161, 2016.

S. K. Rai, T. T. Fung, N. Lu, S. F. Keller, G. C. Curhan et al., The Dietary Approaches to Stop Hypertension (DASH) diet, Western diet, and risk of gout in men: prospective cohort study, BMJ, vol.357, p.1794, 2017.

F. Lioté, S. Lancrenon, S. Lanz, P. Guggenbuhl, C. Lambert et al., GOSPEL: prospective survey of gout in France. Part I: design and patient characteristics (n = 1003), Joint Bone Spine Rev Rhum, vol.79, issue.5, pp.464-70, 2012.

T. Pascart, S. Lancrenon, S. Lanz, C. Delva, P. Guggenbuhl et al., GOSPEL 2-Colchicine for the treatment of gout flares in France-a GOSPEL survey subgroup analysis. Doses used in common practices regardless of renal impairment and age, Joint Bone Spine Rev Rhum, vol.83, issue.6, pp.687-93, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01282350

J. Goossens, S. Lancrenon, S. Lanz, H. Ea, C. Lambert et al., Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century-comparison with 2006 EULAR Recommendations, Joint Bone Spine Rev Rhum, vol.3, issue.4, pp.447-53, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01616224

, World Health Organization, Organization WH. Global Status Report on Alcohol and Health, vol.389, 2014.

B. Escofier and J. Pagès, Analyses factorielles simples et multiples ; objectifs, méthodes et interprétation. Paris: Dunod, vol.318, 2008.

M. Charles, E. Eschwège, and A. Basdevant, Monitoring the obesity epidemic in France: the Obepi surveys 1997-2006. Obes Silver Spring Md, vol.16, pp.2182-2188, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00292589

H. K. Choi and G. Curhan, Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study, BMJ, vol.336, issue.7639, pp.309-321, 2008.

E. Roddy, W. Zhang, and M. Doherty, Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations, Ann Rheum Dis, vol.66, issue.10, pp.1311-1316, 2007.

A. Jeyaruban, M. Soden, and S. Larkins, Prevalence of comorbidities and management of gout in a tropical city in Australia, Rheumatol Int, vol.36, issue.12, pp.1753-1761, 2016.

, Geneva: World Health Organization; 2010 (WHO Guidelines Approved by the Guidelines Review Committee), Global Recommendations on Physical Activity for Health

H. Schneider, E. S. Dietrich, W. Venetz, U. K. France, and A. Us, Trends and stabilization up to 2022 in overweight and obesity in Switzerland, Int J Environ Res Public Health, vol.7, issue.2, pp.460-72, 2010.

F. Nyberg, L. Horne, R. Morlock, J. Nuevo, C. Storgard et al., a Retrospective Analysis, Comorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, vol.33, issue.7, pp.1180-98, 2016.

R. Holland and N. W. Mcgill, Comprehensive dietary education in treated gout patients does not further improve serum urate, Intern Med J, vol.45, issue.2, pp.189-94, 2015.

T. Neogi, C. Chen, J. Niu, C. Chaisson, D. J. Hunter et al., Alcohol Quantity and Type on Risk of Recurrent Gout Attacks: An Internet-based Case-crossover Study, Am J Med, vol.127, issue.4, pp.311-319, 2014.

K. Spencer, A. Carr, and M. Doherty, 3 (20) 65) Gout: Gout duration, years (mean±SD) Number of attacks/year (mean±SD) Presence of tophi, % (n) Serum uric acid, mg/dL (mean±SD) Urate-lowering therapy: % (n) Gout as reason for the consultation, Ann Rheum Dis, vol.71, issue.9, pp.1490-1495, 2012.

, NPM proposed by the physician: At least one NPM proposed, %(n) Number of NPM proposed by the physician

, SD: standard deviation; VAS: visual analogue scale, score between 0 and 100; NPM: nonpharmacological measures; * defined by a creatinine clearance <60ml/min calculated according to the Cockroft-Gault formula